Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue (2016)

Amphastar Pharmaceuticals has reported Current Deferred Revenue over the past 4 years, most recently at $830000.0 for Q3 2016.

  • For Q3 2016, Current Deferred Revenue rose 29.08% year-over-year to $830000.0; the TTM value through Sep 2016 reached $830000.0, up 29.08%, while the annual FY2015 figure was $643000.0, 95.41% down from the prior year.
  • Current Deferred Revenue for Q3 2016 was $830000.0 at Amphastar Pharmaceuticals, down from $1.7 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $14.6 million in Q3 2014 and troughed at $643000.0 in Q4 2013.
  • A 4-year average of $4.1 million and a median of $830000.0 in 2016 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: surged 2079.32% in 2014 and later tumbled 95.59% in 2015.
  • Year by year, Current Deferred Revenue stood at $643000.0 in 2013, then surged by 2079.32% to $14.0 million in 2014, then crashed by 95.41% to $643000.0 in 2015, then grew by 29.08% to $830000.0 in 2016.
  • Business Quant data shows Current Deferred Revenue for AMPH at $830000.0 in Q3 2016, $1.7 million in Q2 2016, and $643000.0 in Q1 2016.